Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab

• DOI: 10.1080/09546634.2024.2334791
• Publication Date: 2024-04-02T23:55:50Z
• Authors: Chenxin Yang; Yang Wang; Ruoyu Li; Ping Tu; Ruojun Wang
• Keywords: Antibodies, Monoclonal; Dermatology; spesolimab; Antibodies, Monoclonal, Humanized; Generalized pustular psoriasis; 03 medical and health sciences; 0302 clinical medicine; Pregnancy; RL1-803; Acute Disease; Chronic Disease; Humans; Psoriasis; biologics; Female; pregnancy; Dermatologic Agents

Generalized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines for the treatment of GPP in pregnancy. Spesolimab, a human monoclonal antibody against the IL-36 receptor, has recently attracted attention as a new therapy for GPP flare. This biologic provides rapid and sustained control of symptoms of GPP flare, although its use in pregnant women has not been reported to date. Here, we report a pregnant woman with refractory GPP who did not respond well to systemic steroids. Administration of spesolimab resulted in complete control of the disease and the birth of a healthy baby. Our case demonstrates that IL-36RN inhibitors are a potentially effective and safe treatment option for GPP in pregnancy.